Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 1,969-1,980 of 4,306
Drug study icon
TerminatedNCT00256997

Risperidone Long-Acting Injection Versus Oral Antipsychotics for schizophrenia

This study was terminated in Australia, in Canada, in the United Kingdom, .... It is testing Risperidone Long-Acting Injection Versus Oral Antipsychotics for schizophrenia.

Multiple locations, including Dandenong
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
Australia, Canada, United Kingdom, ...
Sponsor
Janssen-Ortho Inc., Canada
Condition
Schizophrenia
Drug study icon
CompletedNCT01234779

RO4917838 (Bitopertin) in people with Acute Exacerbation of Schizophrenia

This study is completed in the United States, in Romania, in Russia, .... It is testing RO4917838 (Bitopertin) for schizophrenia.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States, Romania, Russia, ...
Sponsor
Hoffmann-La Roche
Condition
Schizophrenia
Drug study icon
CompletedNCT00616798

RO4917838 for schizophrenia

This study is completed in the United States, in France, in Austria, .... It is testing RO4917838 for schizophrenia.

Multiple locations, including Granada Hills
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 60 Years
Countries
United States, France, Austria, ...
Sponsor
Hoffmann-La Roche
Condition
Schizophrenia
Device study icon
CompletedNCT03273439

RTMS for Cognitive Deficits in Chronic people with Schizophrenia

This study is completed. It is testing rTMS for schizophrenia.

Location not clearly listed
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDeviceA study involving a tool, app, wearable, test, or medical device.From 18 Years to 60 Years
Countries
Sponsor
Suzhou Psychiatric Hospital
Condition
Schizophrenia
Drug study icon
CompletedNCT00077727

Effectiveness of effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in schizophrenia

This study is completed. It is testing effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment for schizophrenia.

Location not clearly listed
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 55 Years
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.